Literature DB >> 7337968

The effect of chronic daily cyclophosphamide administration on established antibody responses.

R F Gagnon, I C MacLennan.   

Abstract

Experiments are described in which the effect of prolonged daily cyclophosphamide administration on established antibody responses is assessed. The antigen used in this study was chicken red blood cells (CRBC) and IgG anti-CRBC antibody production was measured in an antibody-dependent cell-mediated cytotoxicity assay. It is concluded that prolonged administration of cyclophosphamide does cause a small fall in the level of IgG antibody production. This fall, however, is rapidly reversed when the drug is withdrawn. These data suggest that any clinical benefit of cyclophosphamide in the treatment of diseases with autoimmune phenomena may not be due to the action of the drug on antibody-producing cells or their precursors.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7337968      PMCID: PMC1536334     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  39 in total

1.  Therapeutic studies in NZB/W mice. III. Relationship between renal status and efficacy of immunosuppressive drug therapy.

Authors:  A D Steinberg; M C Gelfand; J A Hardin; D T Lowenthal
Journal:  Arthritis Rheum       Date:  1975 Jan-Feb

2.  Anti-glomerular basement membrane antibody-induced glomerulonephritis.

Authors:  C B Wilson; F J Dixon
Journal:  Kidney Int       Date:  1973-02       Impact factor: 10.612

3.  Wegener's granulomatosis.

Authors:  S M Wolff; A S Fauci; R G Horn; D C Dale
Journal:  Ann Intern Med       Date:  1974-10       Impact factor: 25.391

4.  Controlled trial of cyclophosphamide in steroid-sensitive relapsing nephrotic syndrome of childhood.

Authors:  T M Barratt; J F Soothill
Journal:  Lancet       Date:  1970-09-05       Impact factor: 79.321

5.  Immunosuppression by cyclophosphamide in NZB X NZW mice with lupus nephritis.

Authors:  T P Casey
Journal:  Blood       Date:  1968-09       Impact factor: 22.113

6.  Cyclophosphamide treatment of mouse systemic lupus erythematosus.

Authors:  R E Horowitz; E L Dubois; J Weiner; L Strain
Journal:  Lab Invest       Date:  1969-09       Impact factor: 5.662

7.  Effect of irradiation and cyclophosphamide on anti-KLH antibody formation in mice.

Authors:  P E Hoffsten; F J Dixon
Journal:  J Immunol       Date:  1974-02       Impact factor: 5.422

8.  Selective suppression of autoantibody responses in NZB/NZW mice treated with long-term cyclophosphamide.

Authors:  S E Walker; G G Bole
Journal:  Arthritis Rheum       Date:  1975 May-Jun

9.  The clinical pharmacology of antineoplastic agents (second of two parts).

Authors:  B A Chabner; C E Myers; C N Coleman; D G Johns
Journal:  N Engl J Med       Date:  1975-05-29       Impact factor: 91.245

10.  Cyclophosphamide treatment in steroid-sensitive nephrotic syndrome of childhood.

Authors:  T M Barratt; A Bercowsky; S G Osofsky; J F Soothill
Journal:  Lancet       Date:  1975-01-11       Impact factor: 79.321

View more
  1 in total

Review 1.  Approaches to Mitigate the Unwanted Immunogenicity of Therapeutic Proteins during Drug Development.

Authors:  Laura I Salazar-Fontana; Dharmesh D Desai; Tarik A Khan; Renuka C Pillutla; Sandra Prior; Radha Ramakrishnan; Jennifer Schneider; Alexandra Joseph
Journal:  AAPS J       Date:  2017-01-12       Impact factor: 4.009

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.